This study is a prospective open-label, non-randomized multicenter phase I/II trial in order to determine overall response rate of patients with platinum-resistant or refractory recurrent, pretreated epithelial ovarian cancer.
Conditions
Sponsors
University Hospital Heidelberg
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures. 2. Female subjects =18 years of age 3. Histologically or cytologically confirmed diagnosis of: epithelial ovarian cancer which is platinum resistant (relapse-free interval =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Diagnosis of any second malignancy within the last 5 years, with the exception of basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri 2. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug. Screening with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated or if the subject has a history of CNS metastases. 3. Clinically significant gastrointestinal abnormalities which might interfere with oral dosing 4. Any unstable or serious concurrent condition (e.g., active infection requiring systemic therapy). 5. Prolongation of corrected QT interval (QTc) >480 msecs. 6. History of any one or more of the following cardiovascular conditions within the past 6 months: 7. Macroscopic hematuria 8. Hemoptysis that is clinically relevant within 4 weeks of first dose of study drug 9. Evidence of active bleeding or bleeding diathesis 10. Known endobronchial lesions or involvement of large pulmonary vessels by tumor 11. Prior major surgery or trauma within 14 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer. 12. Chemotherapy or radiation therapy within 2 weeks prior to the first dose of study drug. 13. Biological therapy, hormonal therapy or treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer prior to the first dose of study drug. 14. Prior antiangiogenic therapy. 15. Is unable or unwilling to discontinue predefined prohibited medications listed in the protocol for 14 days or five half-lives of a drug (whichever is longer) prior to Visit 1 and for the duration of the study 16. Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity. 17. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib 18. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. 19. Pregnancy (for women of childbearing potential absence to be confirmed by ß-hCG test) or lactation period or missing contraception of women of childbearing potential (Pearl-Index < 1, e.g. hormonal contraception including the combined oral contraceptive pill, the transdermal patch, and the contraceptive vaginal ring, intrauterine devices or sterilization) during treatment and for at least 6 months thereafter. 20. More than 3 different chemotherapy regimens in advanced tumor setting 21. Uncontrolled hypertension 22. History of ischemic event (stroke, myocardial infarction, unstable angina, TIA, symptomatic peripheral vascular disease) 23. History or clinical evidence of thrombo-embolic event 24. Active bleeding 25. Signs/Suspicion of intestinal obstruction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: • Determination of the optimal doses for pazopanib (phase I) • Overall response rate according to RECIST criteria / clinical benefit (stable disease or partial response or complete response) (phase II) ;Secondary Objective: • Time to progression (TTP) • Overall survival • Evaluation of CA125 tumour response • Safety and tolerability • Assessment of quality of life over time as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire ;Primary end point(s): • Determination of the optimal doses for pazopanib (phase I) • Overall response rate according to RECIST criteria / clinical benefit (stable disease or partial response or complete response) (phase II) | — |
Countries
Germany
Contacts
Public ContactPD Dr. Joachim Rom
Universitäts-Frauenklinik
Outcome results
None listed